New antibody cocktail targets Hard-to-Treat prostate cancer
NCT ID NCT06866548
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This early-phase trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC). Seven men with advanced disease that has stopped responding to standard hormone therapy will receive the combination. The main goal is to check safety and side effects, while also measuring how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.